ASH23
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
ASH23
Feb 23, 2024, 14:39 |
Insight
Manni Mohyuddin: Why striving for MRD negativity at all costs and having MRD as a primary endpoint may not be ideal
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Feb 3, 2024, 17:12 |
Positive
Naveen Pemmaraju: Thank you to Jane Fonda for helping us raise so much awareness for research on behalf of our patients with MPNs
Naveen Pemmaraju shared on X/Twitter: "It was amazing to spend a few quality moments with…
Jan 18, 2024, 10:38 |
Insight
Nicola Gökbuget: Time to acknowledge the very successful presentations of the German Multicenter Study Group for Adult ALL
Nicola Gökbuget, Head of Clinical Trial Center at Goethe University Hospital, posted on LinkedIn: "The…
Jan 11, 2024, 19:37 |
Blog
Join us for the upcoming post ASH23 Transplant/CT roundtable by The IACH - International Academy for Clinical Hematology
International Academy for Clinical Hematology made the following post on LinkedIn: "Join us for the…
Jan 1, 2024, 13:48 |
Career
Fumito Ito: I would like to congratulate Manali Begur on receiving an American Society of Hematology Abstract Achievement Award at ASH2023
Fumito Ito, Associate Professor of Surgery at University of Southern California, shared on LinkedIn: "I…
Dec 31, 2023, 12:04 |
Blog
Key updates in the treatment and management of myeloproliferative neoplasms - Video Journal of Hematology and Hematological Oncology
Quoting Video Journal of Hematology and Hematological Oncology on LinkedIn: "NEW MPN Session from ASH23.…
Dec 28, 2023, 18:21 |
Blog
Looking for a career where you can make a difference? - FDA Oncology
Quoting FDA Oncology on X/Twitter: "Looking for a career where you can make a difference?…
Dec 27, 2023, 13:52 |
Blog
Anas Younes: It is time to take a rest to recharge
Anas Younes posted on X/Twitter: "As we get closer to the end of the year,…
Dec 27, 2023, 13:13 |
Insight
Charles Gaulin: Safety of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma
Charles Gaulin, Lymphoma/Myeloma Fellow at MD Anderson Cancer Center, shared on LinkedIn: "At ASH23, we presented…
Dec 24, 2023, 18:13 |
Insight
Oncology Brothers: ASH23 Myeloma Highlights with Jens Hillengass:
Oncology Brothers shared on their X/Twitter page: "ASH23 Myeloma Highlights with Jens Hillengass. - PERSEUS…
Dec 20, 2023, 23:50 |
Blog
Amer Zeidan: Meeting 1st mentor Peter Kouides every The American Society of Hematology (ASH) is a tradition I cherish
Amer Zeidan shared on X/Twitter: “Meeting 1st mentor Peter Kouides every The American Society of Hematology…
Dec 19, 2023, 00:08 |
Blog
Feng Roger Luo: Primary results from a Phase 2 clinical trial evaluating ZYNLONTA® in Chinese patients with relapsed or refractory DLBCL
Feng Roger Luo, Chief Development Officer, Head of Clinical and Preclinical Development at Overland Pharmaceuticals,…
Dec 18, 2023, 23:55 |
Blog
Lucia Masarova: The Best Job we have in medicine is to mentor the next generation of Doctors
Lucia Masarova, Assistant Professor of the Department of Leukemia at MD Anderson Cancer Center, shared…
Dec 18, 2023, 21:10 |
Career
Congratulations to Dr. Ross Levine who was honored by the The Leukemia and Lymphoma Society - Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center shared on LinkedIn: "Congratulations to leukemia specialist and physician-scientist Dr.…
Dec 18, 2023, 13:10 |
Blog
Vincent Rajkumar: Updated treatment approach to newly diagnosed myeloma based on new ASH23 data
Vincent Rajkumar, Editor-in-Chief at Blood Cancer Journal, recently posted on X/Twitter: "Updated treatment approach to…
Dec 17, 2023, 17:14 |
Insight
Ajay Major: Critically important multiple myeloma study from ASH23
Quoting Ajay Major, Assistant Professor at the University of Colorado School of Medicine and Founder…
Dec 17, 2023, 16:48 |
Career
Dr. Omar Abdel-Wahab receives the William Dameshek Prize at ASH23 - Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center posted on X/Twitter: "Congratulations to physician-scientist Dr. Omar Abdel-Wahab, of…
Dec 17, 2023, 16:45 |
Opinion
Manni Mohyuddin: Sad to see surrogacy word loosely used in a plenary session
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, recently…
Dec 17, 2023, 16:13 |
Positive
Mohammad Alhomoud: What would you do when you ran into 2 legendary mentors?
Quoting Mohammad Alhomoud, bone marrow transplant fellow at the Memorial Sloan Kettering Cancer Center, on…
Dec 17, 2023, 01:37 |
Blog
Marco Ruella: So excited to see our discovery make it into human trials!
Marco Ruella, Assistant Professor Of Medicine and Scientific Director Lymphoma Program at University of Pennsylvania,…
Dec 16, 2023, 17:08 |
Blog
Manni Mohyuddin: How to treat myeloma after ASH23
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Dec 15, 2023, 06:30 |
Blog
Anand Patel: Our poster (3192) on allo-HCT in MPN-AP/BP in the current era of myeloid therapies at ASH23
Quoting Anand Patel, Assistant Professor and Director of the Inpatient Leukemia Service at the University…
Dec 15, 2023, 06:27 |
Blog
Jayastu Senapati: Check out our poster on display at ASH23
Jayastu Senapati, Assistant Professor at the Department of Leukemia at MD Anderson Cancer Center, shared…
Dec 15, 2023, 06:01 |
Blog
Othman Al-Sawaf: The primary analysis of the RT1 study just went online at Nature Medicine
Othman Al-Sawaf, haematologist and medical oncologist at the University Hospital Cologne, Cologne, Germany, shared a…
Dec 14, 2023, 23:38 |
Blog
Charles Milrod: It was so much fun talking clinical trials in follicular lymphoma (FL)!
Charles Milrod, Hematology/Oncology fellow Brown University, made the following post on Twitter: "It was so…
Dec 14, 2023, 23:25 |
Blog
We are honored to introduce Mohan Narla as our 2024 President of ASH - The American Society of Hematology
The American Society of Hematology, made the following post on Twitter: "ASH23 has come to…
Dec 14, 2023, 16:06 |
Blog
Nitin Jain: Wonderful to celebrate India’s CD19 CAR T approval
Nitin Jain, the Director of the Leukemia CAR-T Program at the MD Anderson Cancer Center,…
Dec 14, 2023, 15:41 |
Insight
Samer Al Hadidi: Will use of CAR-T earlier be better?
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, made the following post on X/Twitter:…
Dec 14, 2023, 15:36 |
Positive
Akshat Jain: Our force is way too strong to not meet at ASH
Akshat Jain, Hematology Oncology and Stem Cell Therapy specialist and faculty of Clinical Medicine and…
Dec 14, 2023, 12:53 |
Societies
Jill Lykon: We presented our data on toci pre-med prior to teclistamab step up dose
Jill Lykon, Clinical Oncology Pharmacy Manager at the University of Miami Health System, posted on…
Dec 13, 2023, 16:48 |
Blog
Shai Shimony: The prognostic value of molecular ontogeny in AML treated with IC
Shai Shimony, Advanced Clinical Fellow at Dana-Farber Cancer Institute Leukemia Team, shared the following on…
Dec 13, 2023, 08:55 |
Blog
Sanam Loghavi: We had an incredible time representing the American Society of Hematology with trainee quizzes and flashcards and lots of haematology learning
Sanam Loghavi shared a post on LinkedIn: "We had an incredible time representing the American Society…
Dec 12, 2023, 22:50 |
Blog
David Steensma: Terrific Pam Ting described huge body of work identifying WIZ TF as HbF regulator and degrading it
David Steensma, Chief Medical Officer at Ajax Therapeutics, made the following post on Twitter: “When I…
Dec 12, 2023, 20:51 |
Blog
Talha Badar: Dr. Gangat presenting Mayo Clinic Comprehensive Cancer Center data on AML pts Rx with VEN+HMA
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter: "ASH23…
Dec 12, 2023, 20:11 |
Blog
Aaron Goodman: ASH23 - I won't be in attendance but my question would have been
Aaron Goodman shared a post on X/Twitter: “ASH Plenary: 4 active drugs in myeloma makes more…
Dec 12, 2023, 18:18 |
Blog
Joshua Fein: This is a pdf of ASH23 abstracts (no figures, but URLs)
Joshua Fein, Hematology/Oncology Fellow at the Weill Medical College of Cornell University, posted on X/Twitter:…
Dec 11, 2023, 11:21 |
Opinion
Manni Mohyuddin: Vague enrollment criteria in smoldering myeloma trials opens door to harm/over-interventionalism
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Dec 10, 2023, 20:01 |
Blog
Brittany Knick Ragon: If you are searching for a mentor, be sure to find one who brings light to those around them
Brittany Knick Ragon, Director of Hematology Operations, Department of Hematologic Oncology and Blood Disorders at…
Dec 10, 2023, 19:52 |
Blog
We spoke with Nerses Ghahramanyan on challenges that remain in the diagnosis and treatment of BPDCN - The Video Journal of Hematological Oncology
The Video Journal of Hematological Oncology, made the following post on Twitter: "ASH23 | We…
Dec 9, 2023, 16:30 |
Insight
Talha Badar: ASH23, a few selected MDS abstracts to watch out at this year ASH meeting
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:…
Dec 8, 2023, 12:47 |
Insight
Talha Badar: A few selected ALL abstracts to watch for at ASH23
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:…
Dec 5, 2023, 10:32 |
Opinion
Aaron Goodman: ASH23 starts in a week in San Diego my home town!
Aaron Goodman shared on X (Twitter): Tacos ASH23 starts in a week in San Diego…
All:
42
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube